Jubilant HollisterStier is investing $92 million to expand sterile injectable manufacturing capacity at its site in Spokane, WA. The expansion includes the set up of a high-speed, 400 vials a minute, injectable fill line with isolator technology, which will add 50% capacity at the Spokane facility. This expansion will also include two 300 sq.-ft. lyophilizers. The expansion will encompass 50,000 sq.-ft. at the facility and will be commercially operational by the end of 2024. The company began filling new roles to support the expansion and will continue to recruit additional talent.
 
“We are pleased to announce the planned expansion of the sterile injectable manufacturing capacity at this critical juncture. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic and are prepared for a potential future pandemic response. This expansion will also help us meet high demand from our global Specialty Pharmaceutical customers, with whom the company has established strong relationships,” said Pramod Yadav, CEO Jubilant Pharma Ltd.